follow 11/13 Update…IBB down slightly to $104 over two days Trying to hold but choppy in ABBV GILD MRK RHHBY. XBI down 7.1% to $77.28 over one month at 10/24 lows. S&P Core Small Cap IJR down 10.8% over 3 mos.mirroring XBI. Mid-caps mixed but some big winners:AGIO EXEL FOLD IONS NVCR TSRO XNCR. ================ 2018 […]
http://fieldandfire.com/wp-content/plugins/restaurantpress/assets/js/frontend/restaurantpress.min.js?ver=1.7.0 Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]
source Update 10/29 It’s a bear market in biotech so wait for the bottom. Have plenty of cash on hand. IBB at $102.77 down over 5% YTD. Clues: IJR and XBI need to bottom. ======= Update 10/27 Still on vacation, nothing to do . Impossible to trade or invest right now. Sentiment is crushed and numbers […]
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology because […]
lithium medication to buy online Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]
Update-10/1 Rally Fades Early Today…NASDAQ Moves to Red An early rally faded quickly today after an initial spike from new “NAFTA” deal. Biotech ETFs were red IBB down 0.63% and XBI down 1.34%. Mid-Cap biopharmas were mainly red with CAR-T and gene editing stocks hit hard: BLUE CRSP EDIT GWPH NTLA . Will provide news […]
Update 9/26: FED Rate Hike Curbs Traders but Biotech Rolls On The market dipped slightly then went red about 3:30P EDT resulting in a 0.4% loss for the Dow. Main rates will rise to the 2 to 2.25% level with more rate hikes in the future. During Trump’s Press Conference today he said he does not […]
Biotechs Bounce Back: Up From September Lows-Markets Surge Ahead XBI Up 1.66% to $97.16 up from 3 month tech support of $95;IBB up 1.39%. Broad rally brings Dow up 1%, S&P up 0.81% to fresh highs-strong 4 mo. trend line. Sector Winners: Tech (XLK) up 1.18%, Materials (XLB) up 1.08%, Healthcare (XLV) new high up […]
Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]
9/16 The Week That Was: September Trending Down for Biotech NASDAQ-100 Holding (QQQ) at 184 up 1.7% last week. Large caps all weak on Friday; key will be Q3 earnings. FBT, IBB and XBI flat for the week; off highs reached 8/31/18. Mid-caps more mixed with strength in ICPT LGND NBIX NVCR RARE SGEN Healthcare […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.